How to manage <i>Pseudomonas aeruginosa</i> infections.

Details

Ressource 1Download: 29872449_BIB_91C5DC48B249.pdf (504.47 [Ko])
State: Public
Version: Final published version
License: Not specified
Serval ID
serval:BIB_91C5DC48B249
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
How to manage <i>Pseudomonas aeruginosa</i> infections.
Journal
Drugs in context
Author(s)
Bassetti M., Vena A., Croxatto A., Righi E., Guery B.
ISSN
1745-1981 (Print)
ISSN-L
1740-4398
Publication state
Published
Issued date
2018
Peer-reviewed
Oui
Volume
7
Pages
212527
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Abstract
Infections with <i>Pseudomonas aeruginosa</i> have become a real concern in hospital-acquired infections, especially in critically ill and immunocompromised patients. The major problem leading to high mortality lies in the appearance of drug-resistant strains. Therefore, a vast number of approaches to develop novel anti-infectives is currently pursued. Diverse strategies range from killing (new antibiotics) to disarming (antivirulence) the pathogen. In this review, selected aspects of <i>P. aeruginosa</i> antimicrobial resistance and infection management will be addressed. Many studies have been performed to evaluate the risk factors for resistance and the potential consequences on mortality and attributable mortality. The review also looks at the mechanisms associated with resistance - <i>P. aeruginosa</i> is a pathogen presenting a large genome, and it can develop a large number of factors associated with antibiotic resistance involving almost all classes of antibiotics. Clinical approaches to patients with bacteremia, ventilator-associated pneumonia, urinary tract infections and skin soft tissue infections are discussed. Antibiotic combinations are reviewed as well as an analysis of pharmacokinetic and pharmacodynamic parameters to optimize <i>P. aeruginosa</i> treatment. Limitations of current therapies, the potential for alternative drugs and new therapeutic options are also discussed.
Keywords
Pseudomonas aeruginosa, bloodstream infection, ceftazidime-avibactam, ceftolozane-tazobactam, multidrug resistance, new antibiotics, ventilator associated pneumonia
Pubmed
Open Access
Yes
Create date
15/06/2018 17:19
Last modification date
20/08/2019 15:54
Usage data